South Korea’s fertility rate drops to new low
[Chung Chan-seung] The collapse of trust: South Korea's true health care crisis
[Herald Interview] Rival heir to Kim Ju-ae unlikely to appear: unification minister
[KH Explains] Why doctors refuse to bend despite lack of public support
[KH Explains] What does Apple's dead car project mean for Samsung, Hyundai?
Daewoong to start phase 3 trial of COVID-19 preventiveBy Lim Jeong-yeo
Published : Jan. 25, 2021 - 15:13
The company received an approval from the Ministry of Food and Drug Safety to begin the last stage of clinical trials for the drug, Foistar, on Friday.
“Foistar is convenient to administer as oral medication. Its mechanism is expected to work best in the early phase of viral replications. As the drug would hold efficacy against viral mutations, we hope it becomes an optimal preventive measure against further spread of COVID-19,” Daewoong said via a press release.
The drug, which has been in clinical use for over 10 years here against chronic pancreatitis, will be administered on people who have come in close contact with COVID-19 confirmed patients, the company said.
In the trial, a little over 1,000 people will be tested to gauge Foistar’s preventive effects against the novel coronavirus starting February, it added.
Foistar’s active ingredient is camostat mesylate. The drug works as a TMPRSS2 inhibitor, meaning that it obstructs the virus’ pathway into the human cell, by which it suppresses viral growth and reduces inflammation in the human body. It has a lasting efficacy despite viral mutations, Daewoong said.
Daewoong is also seeking to repurpose Foistar to treat COVID-19. While Foistar did not reach statistical significance in its phase 2 clinical trial as a therapy for confirmed COVID-19 patients, the company is continuing to work with governmental authorities to examine Foistar’s efficacy as an independent treatment.
Another ongoing trial is looking at jointly administering Foistar with Gilead Sciences’ remdesivir – which is already used on the medical frontlines -- to treat infected patients.
By Lim Jeong-yeo (email@example.com)
S. Korea, US discuss NK's definition of S. Korea as 'hostile' country
Why doctors refuse to bend despite lack of public support
Cho, Blinken pledge 'watertight' response to any NK provocations